Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Seung‐seob Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6071-306X; OpenAlex author ID A5060502545. Sources: OpenAlex.

Their work

Papers
11 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 6 papers · 2023: none · 2024: 2 papers · 2025: 1 paper

Papers 11

  1. Early response evaluation using CT and CA 19-9 in patients with pancreatic cancer of all stages undergoing first-line FOLFIRINOX treatment. Co-author DOI 10.1016/j.pan.2025.02.007↗
  2. Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.70363↗
  3. Deep-Transfer-Learning-Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Ca… First author DOI 10.1200/cci.24.00021↗
  4. Regional lymph node metastasis detected on preoperative CT and/or FDG-PET may predict early recurrence of pancreatic adenocarcinoma after curative resection. Co-author DOI 10.1038/s41598-022-22126-y↗
  5. Retrospective Evaluation of Treatment Response in Patients with Nonmetastatic Pancreatic Cancer Using CT and CA 19-9. Co-author DOI 10.1148/radiol.212236↗
  6. Laparoscopic distal pancreatosplenectomy for left-sided pancreatic cancer in patients with radical subtotal gastrectomy for gastric cancer. Co-author DOI 10.14701/ahbps.22-016↗
  7. Evaluation of the 8th Edition AJCC Staging System for the Clinical Staging of Pancreatic Cancer. First author DOI 10.3390/cancers14194672↗
  8. Should the Splenic Vein Be Preserved-Fate of Sinistral Portal Hypertension after Pancreatoduodenectomy with Vascular Re-Section for Pancreatic Cancer. First author DOI 10.3390/cancers14194853↗
  9. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis. Co-author DOI 10.5009/gnl20301↗
  10. Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy. Co-author DOI 10.1007/s00261-020-02661-w↗
  11. Radiographic portal or superior mesenteric vein invasion is an independent prognostic factor in non-metastatic pancreatic ductal adenocarcinoma: A missing bloc… First author DOI 10.1016/j.pan.2020.05.017↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mi‐Suk Park · 9 shared papers, 2020–2025 · strength 1.55
  2. Hee Seung Lee · 8 shared papers, 2020–2025 · strength 1.35
  3. Seungmin Bang · 8 shared papers, 2020–2025 · strength 1.35
  4. Ho Kyoung Hwang · 6 shared papers, 2022–2024 · strength 1.05
  5. Jung Hyun Jo · 5 shared papers, 2020–2025 · strength 0.85
  6. Chang Moo Kang · 4 shared papers, 2022–2024 · strength 0.70
  7. Seung Woo Park · 4 shared papers, 2020–2024 · strength 0.56
  8. Moon Jae Chung · 4 shared papers, 2020–2024 · strength 0.56
  9. Jeong Youp Park · 4 shared papers, 2020–2024 · strength 0.56
  10. Woo Jung Lee · 3 shared papers, 2022 · strength 0.52
  11. Sung Hyun Kim · 2 shared papers, 2022–2024 · strength 0.40
  12. Si Young Song · 3 shared papers, 2020–2022 · strength 0.38
  13. Sunyoung Lee · 2 shared papers, 2021–2022 · strength 0.36
  14. Min Sung Yoon · 2 shared papers, 2022–2024 · strength 0.31
  15. Jae Bock Chung · 1 shared paper, 2025 · strength 0.28
  16. Huapyong Kang · 2 shared papers, 2020–2022 · strength 0.25
  17. Choong‐kun Lee · 1 shared paper, 2024 · strength 0.20
  18. Hye Jin Choi · 1 shared paper, 2024 · strength 0.20
  19. Sunkyu Kim · 1 shared paper, 2024 · strength 0.20
  20. Michael Cecchini · 1 shared paper, 2024 · strength 0.20
  21. Kang Hee Lee · 1 shared paper, 2022 · strength 0.19
  22. Seung Soo Hong · 1 shared paper, 2022 · strength 0.19
  23. Jee Hoon Kim · 1 shared paper, 2024 · strength 0.18
  24. Kyung In Shin · 1 shared paper, 2024 · strength 0.18
  25. Myeong‐Jin Kim · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.